Inclusion Body Myositis

被引：78

作者：

Dimachkie, Mazen M. ^{[1
]}

Barohn, Richard J. ^{[2
]}

机构：

[1] Univ Kansas, Med Ctr, Dept Neurol, Neurophysiol Div,Neuromuscular Sect, Kansas City, KS 66160 USA

[2] Univ Kansas, Med Ctr, Dept Neurol, Kansas City, KS 66160 USA

来源：

NEUROLOGIC CLINICS | 2014年 / 32卷 / 03期

关键词：

Inclusion body myositis; Idiopathic inflammatory myopathies; Polymyositis; Diagnosis; Pathology; Pathophysiology; Treatment; Prognosis; CYTOSOLIC 5'-NUCLEOTIDASE 1A; QUANTITATIVE ASSESSMENT; PILOT TRIAL; CLINICAL-COURSE; MUSCLE; BETA; EPIDEMIOLOGY; EXPLANATION; PREVALENCE; DISEASE;

D O I：

10.1016/j.ncl.2014.04.001

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The idiopathic inflammatory myopathies (IIMs) are a heterogenous group of rare disorders that share many similarities. In addition to sporadic inclusion body myositis (IBM), these include dermatomyositis, polymyositis, and autoimmune necrotizing myopathy. IBM is the most common IIM after age 50 years. Muscle histopathology shows endomysial inflammatory exudates surrounding and invading nonnecrotic muscle fibers often accompanied by rimmed vacuoles and protein deposits. It is likely that IBM has a prominent degenerative component. This article reviews the evolution of knowledge in IBM, with emphasis on recent developments in the field, and discusses ongoing clinical trials.

引用

页码：629 / +

页数：19

共 78 条

[1] Inclusion body myositis: old and new concepts [J].

Amato, A. A. ;

Barohn, R. J. .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2009, 80 (11) :1186-1193

[2] Inclusion body myositis: Clinical and pathological boundaries [J].

Amato, AA ;

Gronseth, GS ;

Jackson, CE ;

Wolfe, GI ;

Katz, JS ;

Bryan, WW ;

Barohn, RJ .

ANNALS OF NEUROLOGY, 1996, 40 (04) :581-586

[3] INCLUSION-BODY MYOSITIS - TREATMENT WITH INTRAVENOUS IMMUNOGLOBULIN [J].

AMATO, AA ;

BAROHN, RJ ;

JACKSON, CE ;

PAPPERT, EJ ;

SAHENK, Z ;

KISSEL, JT .

NEUROLOGY, 1994, 44 (08) :1516-1518

[4] Sporadic inclusion body myositis: Pilot study on the effects of a home exercise program on muscle function, histopathology and inflammatory reaction [J].

Arnardottir, S ;

Alexanderson, H ;

Lundberg, IE ;

Borg, K .

JOURNAL OF REHABILITATION MEDICINE, 2003, 35 (01) :31-35

[5] Inclusion-body myositis -: A myodegenerative conformational disorder associated with Aβ, protein misfolding, and proteasome inhibition [J].

Askanas, V ;

Engel, WK .

NEUROLOGY, 2006, 66 :S39-S48

[6]

Askanas Valerie, 2011, Presse Med, V40, pe219, DOI 10.1016/j.lpm.2010.11.024

[7] Epidemiology of inclusion body myositis in the Netherlands:: A nationwide study [J].

Badrising, UA ;

Maat-Schieman, M ;

van Duinen, SG ;

Breedveld, F ;

van Doorn, P ;

van Engelen, B ;

van den Hoogen, F ;

Hoogendijk, J ;

Höweler, C ;

de Jager, A ;

Jennekens, F ;

Koehler, P ;

van der Leeuw, H ;

de Visser, M ;

Verschuuren, JJ ;

Wintzen, AR .

NEUROLOGY, 2000, 55 (09) :1385-1387

[8] Inclusion body myositis - Clinical features and clinical course of the disease in 64 patients [J].

Badrising, UA ;

Maat-Schieman, MLC ;

van Houwelingen, JC ;

van Doorn, PA ;

van Duinen, SG ;

van Engelen, BGM ;

Faber, CG ;

Hoogendijk, JE ;

de Jager, AE ;

Koehler, PJ ;

de Visser, M ;

Verschuuren, JJGM ;

Wintzen, AR .

JOURNAL OF NEUROLOGY, 2005, 252 (12) :1448-1454

[9] Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo [J].

Badrising, UA ;

Maat-Schieman, MLC ;

Ferrari, MD ;

Zwinderman, AH ;

Wessels, JAM ;

Breedveld, FC ;

van Doorn, PA ;

van Engelen, BGM ;

Hoogendijk, JE ;

Höweler, CJ ;

de Jager, AE ;

Jennekens, FGI ;

Koehler, PJ ;

de Visser, M ;

Viddeleer, A ;

Verschuuren, JJ ;

Wintzen, AR .

ANNALS OF NEUROLOGY, 2002, 51 (03) :369-372

[10] Inclusion body myositis [J].

Richard J. Barohn ;

Anthony A. Amato .

Current Treatment Options in Neurology, 2000, 2 (1) :7-11

← 1 2 3 4 5 6 7 8 →